Phaseline

Targets › IL7R

IL7R (Interleukin-7 receptor subunit alpha): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout May 2028.

Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). (UniProt, P16871)

Open in Phaseline: the race on IL7R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Allterum Therapeutics4A10 (Molecule B4532)
Anti-CD127 (IL-7Rα) monoclonal antibody
IL7RPhase 1Lymphoblastic LymphomaMay 2028
Chulalongkorn UniversityCMD63
CD19-targeted CAR-T cell with IL-7Rα signaling domain
CD19, IL7RPhase 1Relapse B Acute Lymphoblastic LeukemiaSep 2028

Conditions

Lymphoblastic Lymphoma (1) Relapse B Acute Lymphoblastic Leukemia (1)

Modalities

small molecule (1), other (1)

Companies

Allterum Therapeutics (1) Chulalongkorn University (1)

Related targets

CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.